Medtronic sued by doctor for alleged patent infringement

Pelvic surgery consultancy group Hexagon Health and its founder Shirin Towfigh, MD, have filed a lawsuit against Medtronic, alleging that the medical device company infringed on patents related to hernia mesh treatments.

Towfigh claims that Medtronic is manufacturing devices that utilize three patents owned by her and Hexagon Health, specifically a hernia repair device known as Dextile, which features a novel fin shape for broader mesh coverage.

The device was designed by Towfigh, and the patents were awarded to her and Hexagon Health by the U.S. Patent and Trademark Office, according to the lawsuit. Towfigh, a hernia repair surgeon, developed the mesh to address common post-surgery injuries her patients were experiencing.

Medtronic allegedly continued to manufacture and sell Dextile, modeled after Towfigh’s patents.

Medtronic Dextile Website Screenshot
Dextile, as it appears on Medtronic's website.

"Medtronic's improper use of Hexagon Health's hernia mesh designs has cost Dr. Towfigh significant financial gain and created a disincentive for other physician-entrepreneurs to enter the medical device marketplace with innovative products for patients in need," Nicholas Groombridge, Hexagon Health's attorney and partner at the law firm Groombridge, Wu, Baughman & Stone, said in a statement.

Details of the damages being sought in the lawsuit have not been disclosed. Medtronic has yet to respond to the claim but has been issued a summons, according to updates on the federal court tracker PacerMonitor. The lawsuit was filed in a Delaware court on Nov. 12.

Dextile is still listed for sale on Medtronic’s website

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.